ValueQ4, 24TTMSelling/general/admin expenses123.02 M518.73 MResearch & development213.25 M825 MOperating income235.22 M872.19 MNon-Operating Income, Total46 K-198 KInterest expense, net of interest capitalized——Non-Operating Income, excl. Interest Expenses00Unusual income/expense46 K-198 KPretax income235.26 M871.99 MEquity in earnings——Taxes8.16 M158.64 MNon-controlling/minority interest——After tax other income/expense2.35 M11.61 MNet income before discontinued operations244.53 M782.57 MDiscontinued operations——Net income244.53 M782.57 MDilution adjustment——Preferred dividends——Diluted net income available to common stockholders244.53 M782.57 MBasic earnings per share (Basic EPS)0.912.88Diluted earnings per share (Diluted EPS)0.892.78Average basic shares outstanding271.57 M1.09 BDiluted shares outstanding281.86 M1.13 BEBITDA242.16 M901.25 MEBIT235.22 M872.19 MCost of revenue26.48 M83.7 MOther cost of goods sold——Depreciation & amortization (cash flow)6.95 M29.05 M
Exelixis Inc
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.